Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Payables: 2015-2024

Historic Payables for Spyre Therapeutics (SYRE) over the last 10 years, with Dec 2024 value amounting to $666,000.

  • Spyre Therapeutics' Payables rose 44.38% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.5 million, marking a year-over-year decrease of 61.68%. This contributed to the annual value of $666,000 for FY2024, which is 95.98% down from last year.
  • Per Spyre Therapeutics' latest filing, its Payables stood at $666,000 for FY2024, which was down 95.98% from $16.6 million recorded in FY2023.
  • Over the past 5 years, Spyre Therapeutics' Payables peaked at $16.6 million during FY2023, and registered a low of $666,000 during FY2024.
  • Moreover, its 3-year median value for Payables was $677,000 (2022), whereas its average is $6.0 million.
  • In the last 5 years, Spyre Therapeutics' Payables skyrocketed by 2,349.63% in 2023 and then crashed by 95.98% in 2024.
  • Over the past 5 years, Spyre Therapeutics' Payables (Yearly) stood at $2.3 million in 2020, then soared by 47.25% to $3.3 million in 2021, then crashed by 79.60% to $677,000 in 2022, then soared by 2,349.63% to $16.6 million in 2023, then slumped by 95.98% to $666,000 in 2024.